Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,708.00INR
2:14pm IST
Change (% chg)

Rs15.60 (+0.58%)
Prev Close
Rs2,692.40
Open
Rs2,699.80
Day's High
Rs2,712.00
Day's Low
Rs2,682.65
Volume
15,418
Avg. Vol
35,700
52-wk High
Rs3,580.00
52-wk Low
Rs2,382.05

REDY.BO

Chart for REDY.BO

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.11
Market Cap(Mil.): Rs447,127.81
Shares Outstanding(Mil.): 165.82
Dividend: 20.00
Yield (%): 0.74

Financials

  REDY.BO Industry Sector
P/E (TTM): 34.80 13.56 17.15
EPS (TTM): 77.48 -- --
ROI: -- -7.26 -5.60
ROE: -- -6.80 -4.89

BRIEF-Dr.Reddy's Labs says audit of Mexican plant by USFDA completed with zero observations

* Says audit of our API Cuernavaca plant at Mexico, by US FDA, has been completed with zero observations Source text for Eikon: Further company coverage:

21 Jul 2017

BRIEF-Dr. Reddy's Lab says USFDA issues form 483 with one observation for Srikakulam Plant

* Says formulations Srikakulam Plant (SEZ) unit I, Andhra Pradesh, by US FDA, has been completed Friday

16 Jun 2017

BRIEF-Dr.Reddy's Labs recalls Cipla-made zenatane capsule from U.S. markets

* Dr.Reddy's Laboratories clarifies on news item, "Dr Reddy's recalls 3.25l cartons Cipla-made acne drug from US".

15 Jun 2017

BRIEF-Dr.Reddy's Labs gets EIR as closure of audit of Miryalaguda API manufacturing plant

* Says got EIR after audit of API manufacturing plant at Miryalaguda, by US FDA, as closure of audit Source text - (http://bit.ly/2smE0VK) Further company coverage:

14 Jun 2017

BRIEF-Dr.Reddy's Laboratories announces launch of Bivalirudin for injection in U.S. market

* Says announces launch of Bivalirudin for injection in U.S. market Source text for Eikon: Further company coverage:

06 Jun 2017

BRIEF-Dr.Reddy's Labs' audit of formulations Srikakulum plant Unit II completed with zero observations

* Says audit of formulations Srikakulum Plant unit II, Andhra Pradesh by US FDA, completed with zero observations. Source text - (http://bit.ly/2qnkt2M) Further company coverage:

25 May 2017

BRIEF-Dr.Reddy's Laboratories says USFDA approved launch of doxorubicin hydrochloride liposome injection in U.S.

* Announces USFDA approval for launch of doxorubicin hydrochloride liposome injection in U.S. Market Source text - (http://bit.ly/2qQ6RC6) Further company coverage:

17 May 2017

BRIEF-India's Dr.Reddy's Laboratories March-qtr consol profit rises about three-fold

* Consensus forecast for March quarter consol profit was 4.27 billion rupees

12 May 2017

BRIEF-Dr. Reddy's Labs launches Ezetimibe and Simvastatin tablets in U.S. market

* Says launch of Ezetimibe and Simvastatin tablets in U.S. market Source text for Eikon: Further company coverage:

27 Apr 2017

BRIEF-Fresenius sees no change in relationship of Merck KGaA's unit with partner Dr Reddy's

* Fresenius ceo sturm says we've had a good q1 but will not provide details

25 Apr 2017

Earnings vs. Estimates